

## Short Communication

# Generalizability of Associations from Prostate Cancer Genome-Wide Association Studies in Multiple Populations

Kevin M. Waters,<sup>1</sup> Loic Le Marchand,<sup>2</sup> Laurence N. Kolonel,<sup>2</sup> Kristine R. Monroe,<sup>1</sup> Daniel O. Stram,<sup>1</sup> Brian E. Henderson,<sup>1</sup> and Christopher A. Haiman<sup>1</sup>

<sup>1</sup>Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California and <sup>2</sup>Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii

### Abstract

Genome-wide association studies have identified multiple common alleles associated with prostate cancer risk in populations of European ancestry. Testing these variants in other populations is needed to assess the generalizability of the associations and may guide fine-mapping efforts. We examined 13 of these risk variants in a multiethnic sample of 2,768 incident prostate cancer cases and 2,359 controls from the Multiethnic Cohort (African Americans, European Americans, Latinos, Japanese Americans, and Native Hawaiians). We estimated ethnic-specific and pooled odds ratios and tested for ethnic heterogeneity of effects using logistic regression. In ethnic-pooled analyses, 12 of the 13 variants were positively associated with risk, with statistically significant associations ( $P < 0.05$ ) noted with six variants: *JAZF1*, rs10486567 [odds ratio (OR), 1.23; 95% confidence interval (95% CI), 1.12-1.35]; Xp11.2, rs5945572 (OR, 1.31; 95% CI, 1.13-1.51); *HNF1B*, rs4430796 (OR, 1.15; 95% CI, 1.06-1.25); *MSMB*, rs10993994 (OR, 1.13; 95% CI, 1.04-1.23); 11q13.2, rs7931342 (OR, 1.13; 95% CI, 1.03-1.23);

3p12.1, rs2660753 (OR, 1.11; 95% CI, 1.01-1.21); *SLC22A3*, rs9364554 (OR, 1.10; 95% CI, 1.00-1.21); *CTBP2*, rs12769019 (OR, 1.11; 95% CI, 0.99-1.25); *HNF1B*, rs11649743 (OR, 1.10; 95% CI, 0.99-1.22); *EHBP1*, rs721048 (OR, 1.08; 95% CI, 0.94-1.25); *KLK2/3*, rs2735839 (OR, 1.06; 95% CI, 0.97-1.16); 17q24.3, rs1859962 (OR, 1.04; 95% CI, 0.96-1.13); and *LMTK2*, rs6465657 (OR, 0.99; 95% CI, 0.89-1.09). Significant ethnic heterogeneity of effects was noted for four variants (*EHBP1*,  $P_{\text{het}} = 3.9 \times 10^{-3}$ ; 11q13,  $P_{\text{het}} = 0.023$ ; *HNF1B* (rs4430796),  $P_{\text{het}} = 0.026$ ; and *KLK2/3*,  $P_{\text{het}} = 2.0 \times 10^{-3}$ ). Although power was limited in some ethnic/racial groups due to variation in sample size and allele frequencies, these findings suggest that a large fraction of prostate cancer variants identified in populations of European ancestry are global markers of risk. For many of these regions, fine-mapping in non-European samples may help localize causal alleles and better determine their contribution to prostate cancer risk in the population. (Cancer Epidemiol Biomarkers Prev 2009;18(4):1285-9)

### Introduction

Genome-wide association studies in men of European ancestry have revealed multiple variants consistently associated with prostate cancer risk (1-5). Testing of these risk alleles across populations is an important first step to address the pan-ethnic nature of their associations, as differences in linkage disequilibrium and minor allele frequencies may make it difficult to generalize the associations to populations of non-European descent. We have recently shown the power that multiethnic genetic studies of common complex diseases possess, having revealed a number of common variants for prostate cancer at 8q24 that were not identified in larger comprehensive studies in populations of European ancestry (6). In the present study, we have evaluated 13

variants considered to be established risk variants for prostate cancer among men of European ancestry in association with prostate cancer risk in a large multiethnic case-control study.

### Materials and Methods

**Study Population.** The Multiethnic Cohort Study is a population-based prospective cohort study that was initiated between 1993 and 1996 and includes subjects from various ethnic groups—African Americans and Latinos primarily from California (mainly Los Angeles) and Native Hawaiians, Japanese Americans, and European Americans primarily from Hawaii (7). State driver's license files were the primary sources used to identify study subjects in Hawaii and California. Additionally, in Hawaii, state voter's registration files were used, and, in California, Health Care Financing Administration files were used to identify additional African American men.

All participants ( $N = 215,251$ ) returned a 26-page self-administered baseline questionnaire that obtained general demographic, medical, and risk factor information. In the cohort, incident cancer cases are identified annually through cohort linkage to population-based

Received 12/2/08; revised 1/22/09; accepted 2/13/09; published OnlineFirst 3/24/09.

**Grant support:** The Multiethnic Cohort Study was supported by National Cancer Institute grants CA63464 and CA54281. Partial salary support was also provided by National Human Genome Research Institute grant 1U01HG004802.

**Requests for reprints:** Kevin Waters, Harlyne Norris Research Tower, 1450 Biggy Street, Room 1516, Los Angeles, CA 90033. Phone: 323-442-7785; Fax: 323-865-0127. E-mail: kwaters@usc.edu

Copyright © 2009 American Association for Cancer Research.

doi:10.1158/1055-9965.EPI-08-1142

cancer Surveillance, Epidemiology, and End Results registries in Hawaii and Los Angeles County as well as to the California State cancer registry. Information on stage and grade of disease is also obtained through the Surveillance, Epidemiology, and End Results registries.

Blood sample collection in the Multiethnic Cohort Study began in 1994 and targeted incident prostate cancer cases and a random sample of study participants to serve as controls for genetic analyses. This nested prostate cancer case-control study in the Multiethnic Cohort Study consists of 2,768 invasive prostate cancer cases and 2,359 controls. This study was approved by the institutional review boards at the University of Southern California and at the University of Hawaii, and informed consent was obtained from all study participants.

**Laboratory Assays.** Genotyping for this study was performed using genomic DNA samples, and the allelic discrimination assay (8). The assay for rs4962416, which was previously reported as a risk allele near the CTBP2 gene (4), failed in genotyping so it was replaced by rs12769019 for association testing of this risk allele (pairwise  $r^2 = 1.0$  in the hapmap CEU population). We included ~5% duplicate samples to assess genotyping reproducibility. In total, the concordance was 99.9% among the replication sets. For the 13 variants, the overall genotyping call rate was 98.7%. Call rates were also similar between cases and controls for each population (largest difference was 5.5% for rs5945572 in African Americans). For each variant, we examined Hardy-Weinberg equilibrium using a  $\chi^2$  test (1 *df*) among the controls for each ethnic group. Three variants were nominally statistically significant (rs2660753, European Americans,  $P = 0.035$ ; rs9364554, Japanese Americans,  $P = 0.047$ ; and rs2735839, European Americans,  $P = 0.035$ ). Based on the number of tests, we would have expected ~3 of these tests to be significant by chance alone. Details regarding genotyping efficiency and Hardy-Weinberg equilibrium are provided in Supplementary Table S1.

**Statistical Analysis.** Odds ratios (OR) and 95% confidence intervals (95% CI) of the effect of each variant on prostate cancer risk were computed using logistic regression in ethnic-specific and ethnic-pooled analyses (SAS version 9.1, SAS Institute, Inc.). We estimated the log-additive effect of each risk allele as well as the OR for heterozygotes and homozygotes separately. All estimates are adjusted for age (quintiles) and race (in pooled analysis). In the admixed populations (African Americans, Latinos, and Native Hawaiians), we adjusted for their global proportion of European ancestry as previously described (6). First-degree family history of prostate cancer (father or full brother) was also examined as a potential confounding variable, but was not included in the model because it had no effect (<2% change) on the pooled risk associations. We tested for allelic heterogeneity of effects by including an interaction term between variant and racial/ethnic group in the regression model (4 *df* test). We also tested for gene  $\times$  gene interaction by including an interaction term for every combination of two risk alleles. We also examined genetic associations with prostate cancer risk among disease subgroups using the standard case-control approach, limiting the cases to those with a specific phenotype ("advanced disease")

and all controls, and a case-only analysis to test for differences by disease subgroup. We defined the cancer as advanced if high stage (regional by direct extension, and/or regional by lymph nodes, regional not otherwise specified, or distant metastases/systemic disease), and/or high grade (low level of cell differentiation; Gleason score >7). Nonadvanced disease was defined as having both a localized stage and low grade (Gleason score  $\leq 7$ ). We were unable to define cases as either advanced or localized if both stage and grade data were missing or if either the stage was localized or grade was low (Gleason score  $\leq 7$ ), and information for the other variable was missing ( $n = 207$ ).

## Results and Discussion

Cases in this study ranged in age of entry into the cohort from 44 to 78 years with a mean of 64.3 years (age at diagnosis ranged from 46 to 87 years). Controls ranged in age from 45 to 77 years with a mean of 62.5 years. The Japanese Americans were slightly older (mean age of entry, 64.6 years), whereas the Native Hawaiians were slightly younger than the other three groups (mean age of entry, 62.7 years).

Six of the variants were nominally statistically significant ( $P < 0.05$ ) in pooled analyses [JAZF1, rs10486567 (OR, 1.23; 95% CI, 1.12-1.35); Xp11.2, rs5945572, (OR, 1.31; 95% CI, 1.13-1.51); HNF1B, rs4430796 (OR, 1.15; 95% CI, 1.06-1.25); MSMB, rs10993994, (OR, 1.13; 95% CI, 1.04-1.23); 11q13.2, rs7931342 (OR, 1.13; 95% CI, 1.03-1.23), and 3p12.1, rs2660753 (OR, 1.11; 95% CI, 1.01-1.21); Table 1]. These associations were similar in magnitude and in the same direction as reported in previous genome-wide association studies among men of European ancestry (1-5). The associations for each genotype class are provided in Supplementary Table S2. These six risk variants were common in all populations with frequencies ranging from 0.06 to 0.76, and frequencies  $\geq 0.19$  in the combined sample. For two variants, we detected significant heterogeneity of the effect across populations (HNF1B, rs4430796,  $P_{\text{het}} = 0.026$ ; 11q13.2, rs7931342,  $P_{\text{het}} = 0.023$ ). For these variants, positive associations were noted in all populations except African Americans and Japanese, respectively, the two largest groups, suggesting that these variants are poorly linked to the causal alleles in these populations.

Nonsignificant positive associations were also observed in the expected direction for six other variants [SLC22A3, rs9364554 (OR, 1.10; 95% CI, 1.00-1.21); CTBP2, rs12769019 (OR, 1.11; 95% CI, 0.99-1.25); HNF1B, rs11649743 (OR, 1.10; 95% CI, 0.99-1.22); EHBP1, rs721048 (OR, 1.08; 95% CI, 0.94-1.25); KLK2/3, rs2735839 (OR, 1.06; 95% CI, 0.97-1.16); and 17q24.3, rs1859962 (OR, 1.04; 95% CI, 0.96-1.13)]; for most of these variants, positive associations were observed consistently across populations (Table 1). Two of these variants had frequencies <0.20 in the combined sample with ethnic-specific frequencies <0.05 in some populations. We noted significant ethnic heterogeneity in the associations for EHBP1 (rs721048,  $P_{\text{het}} = 3.9 \times 10^{-3}$ ) and KLK2/3 (rs2735839,  $P_{\text{het}} = 2.0 \times 10^{-3}$ ; Table 1) and no evidence of an association with variant rs6465657 in LMTK2 (OR, 0.99; 95% CI, 0.89-1.09). Interestingly, the KLK2/3 variant was inversely associated with risk in African Americans.

**Table 1. Frequencies of risk alleles and associations with prostate cancer risk in the MEC**

SNP	Chr./Nearest Gene	Allele tested	OR (95% CI)* / Risk Allele Frequency					Pooled (2,768 ca/2,359 co)	P	P <sub>het</sub> <sup>†</sup>
			African Americans (860 ca/575 co)	European Americans (468 ca/419 co)	Latinos (603 ca/572 co)	Japanese Americans (725 ca/684 co)	Native Hawaiians (112 ca/109 co)			
rs721048	2p15 <i>EHBP1</i>	A	0.86 (0.59-1.26) 0.05	0.87 (0.67-1.12) 0.19	1.49 (1.19-1.87) 0.14	1.05 (0.71-1.56) 0.04	0.52 (0.24-1.12) 0.09	1.08 (0.94-1.25) 0.09	0.26	3.9 × 10 <sup>-3</sup>
rs2660753	3p12.1	T	0.97 (0.83-1.14) 0.46	1.06 (0.81-1.39) 0.13	1.15 (0.94-1.40) 0.20	1.30 (1.09-1.55) 0.24	0.94 (0.56-1.57) 0.18	1.11 (1.01-1.21) 0.26	0.034	0.16
rs9364554	6q25.3 <i>SLC22A3</i>	T	1.10 (0.82-1.48) 0.07	1.06 (0.86-1.30) 0.27	1.15 (0.95-1.39) 0.21	1.09 (0.93-1.29) 0.34	1.07 (0.69-1.68) 0.22	1.10 (1.00-1.21) 0.47	0.062	0.99
rs10486567	7p15.2 <i>JAZF1</i>	G	1.18 (1.00-1.40) 0.70	1.50 (1.19-1.89) 0.74	1.19 (1.00-1.40) 0.53	1.14 (0.88-1.48) 0.09	1.25 (0.83-1.89) 0.36	1.23 (1.12-1.35) 0.47	2.1 × 10 <sup>-5</sup>	0.48
rs6465657	7q21.3 <i>LMTK2</i>	C	0.91 (0.72-1.14) 0.85	1.08 (0.89-1.31) 0.45	0.94 (0.78-1.12) 0.70	1.04 (0.82-1.33) 0.90	0.98 (0.65-1.49) 0.67	0.99 (0.89-1.09) 0.75	0.80	0.77
rs10993994	10q11.23 <i>MSMB</i>	T	1.05 (0.90-1.24) 0.59	1.15 (0.96-1.39) 0.42	1.06 (0.90-1.25) 0.37	1.26 (1.08-1.46) 0.45	1.10 (0.75-1.61) 0.64	1.13 (1.04-1.23) 0.47	3.1 × 10 <sup>-3</sup>	0.52
rs12769019	10q26.13 <i>CTBP2</i>	G	1.20 (0.98-1.47) 0.16	1.12 (0.90-1.39) 0.26	1.00 (0.83-1.21) 0.24	1.43 (0.75-2.76) 0.01	1.42 (0.68-2.95) 0.07	1.11 (0.99-1.25) 0.15	0.062	0.60
rs7931342	11q13.2	G	1.12 (0.93-1.35) 0.76	1.28 (1.05-1.55) 0.51	1.27 (1.07-1.51) 0.37	0.87 (0.73-1.05) 0.23	1.19 (0.79-1.80) 0.48	1.13 (1.03-1.23) 0.45	8.4 × 10 <sup>-3</sup>	0.023
rs11649743	17q12 <i>HNF1B</i>	G	1.04 (0.79-1.38) 0.91	1.05 (0.82-1.35) 0.82	1.29 (1.04-1.61) 0.82	1.08 (0.91-1.27) 0.70	0.96 (0.65-1.41) 0.62	1.10 (0.99-1.22) 0.80	0.067	0.58
rs4430796	17q12 <i>HNF1B</i>	A	0.99 (0.84-1.16) 0.35	1.44 (1.18-1.74) 0.48	1.26 (1.07-1.50) 0.57	1.04 (0.89-1.22) 0.64	1.23 (0.79-1.90) 0.70	1.15 (1.06-1.25) 0.53	9.1 × 10 <sup>-4</sup>	0.026
rs1859962	17q24.3	G	1.01 (0.86-1.19) 0.32	1.00 (0.83-1.20) 0.51	1.10 (0.93-1.30) 0.60	1.06 (0.89-1.25) 0.26	1.03 (0.69-1.52) 0.56	1.04 (0.96-1.13) 0.42	0.35	0.95
rs2735839	19q13 <i>KLK2/3</i>	G	0.80 (0.67-0.95) 0.71	1.33 (1.02-1.75) 0.84	1.15 (0.94-1.40) 0.77	1.21 (1.03-1.41) 0.58	0.91 (0.61-1.35) 0.51	1.06 (0.97-1.16) 0.70	0.20	2.0 × 10 <sup>-3</sup>
rs5945572	Xp11.22 <i>NUDT10/11</i>	A	1.34 (1.05-1.71) 0.26	1.25 (0.95-1.66) 0.35	1.32 (0.98-1.77) 0.17	1.25 (0.86-1.82) 0.08	1.65 (0.61-4.46) 0.06	1.31 (1.13-1.51) 0.19	2.6 × 10 <sup>-4</sup>	0.98

Abbreviations: SNP, single nucleotide polymorphism; Chr., chromosome; ca, cancer; co, control.

\*ORs were adjusted for age (quintiles), genome-wide European ancestry (African Americans, Latinos, and Native Hawaiians) and age-ethnicity strata (pooled analysis).

<sup>†</sup>P<sub>het</sub> = P value for heterogeneity of allelic effects across ethnic groups (4 df test).

The original genome-wide association studies found effect sizes of 1.10 to 1.25 per allele with frequencies of the risk alleles ranging from 0.10 to 0.85 (1-5). A replication study of seven of these alleles by the PRACTICAL Consortium found per allele effect sizes ranging from 1.08 to 1.30 (9). In our study, a lack of power due to smaller sample size and/or low minor allele frequencies in some populations (and thus in the combined sample) was likely to contribute to some of the variants not reaching statistical significance. We had relatively limited power (50-65%) to detect statistically significant pooled effects of 1.10 to 1.12 for variants with frequencies as low as 0.20. Power was improved ( $\geq 81\%$ ) for effects  $\geq 1.20$  and risk alleles with frequencies  $\geq 0.10$  in the combined sample.

We detected six significant gene  $\times$  gene interactions; however, it is difficult to determine whether any of these are true effects, because this analysis included 78 tests and we would have expected  $\sim 4$  significant interactions by chance alone. The most significant interaction ( $P = 9.0 \times 10^{-3}$ ) was between rs4430796 (*HNF1B*) and rs1859962 (17q24), which are both located on the same chromosome, albeit in distant areas.

We also examined allelic associations by disease subgroup (advanced versus nonadvanced; Table 2; Supplementary Tables S3 and S4) and tested for differences in case-only analyses. None of the differences in prostate cancer risk between advanced and nonadvanced subgroups were statistically significant.

Although the majority of the risk variants examined in this study were positively associated with risk in the pooled analysis, the lack of consistent effects in all populations for some markers suggests that, for these associations, the underlying causal variant may not be of

appreciable frequency in all populations and/or differences in linkage disequilibrium may be obscuring effects in some populations. One example where this is likely to be the case is rs4430796 (*HNF1B*), where we noted no evidence of an association in African Americans (OR, 0.99; 95% CI, 0.84-1.16). The ethnic heterogeneity observed for some markers may also be due to interactions with other genetic risk factors and environmental exposures that vary in frequency across populations, which we plan to explore in future analyses.

Our previous studies on 8q24 and prostate cancer provide strong support for the hypothesis that the higher incidence of prostate cancer in African American men, compared with men in other racial and ethnic populations, is due to common risk variants that are more common in men of African descent (6). It is interesting to note that only three of the variants examined in this study were more common in African Americans than in the other racial/ethnic groups (Table 1). Fine mapping of these candidate prostate cancer risk loci in a multiethnic sample will be important to identify the strongest markers of risk in each population and hopefully will help us to better understand the excess risk of prostate cancer in African Americans.

Among the alleles examined, very little is known about the genes involved and/or the potential biological mechanisms underlying their association with prostate cancer risk. None of the risk variants examined in this study are located in exons. Decreased serum levels of the protein product of *MSMB*, Prostate Secretory Protein of 94 amino acids, has been associated with increased prostate cancer risk (10). *MSMB* may be a tumor suppressor and altering its expression could play an important role in tumorigenesis. *HNF1B*, a transcription factor, is involved

**Table 2. Associations with prostate cancer by disease subgroup and case-only testing**

SNP	Chr./Nearest Gene	Allele tested	OR (95% CI)* / Risk allele frequency		$P_{\text{het}}^{\dagger}$
			Advanced cases (961 ca/2,359 co)	Nonadvanced cases (1,600 ca/2,359 co)	
rs721048	2p15 <i>EHBP1</i>	A	1.00 (0.82-1.21) 0.09	1.11 (0.94-1.30) 0.09	0.33
rs2660753	3p12.1	T	1.15 (1.01-1.30) 0.26	1.06 (0.96-1.19) 0.26	0.26
rs9364554	6q25.3 <i>SLC22A3</i>	T	1.06 (0.93-1.21) 0.22	1.12 (0.99-1.25) 0.22	0.53
rs10486567	7p15.2 <i>JAZF1</i>	G	1.13 (0.99-1.29) 0.47	1.31 (1.17-1.46) 0.47	0.088
rs6465657	7q21.3 <i>LMTK2</i>	C	0.95 (0.83-1.08) 0.75	1.04 (0.93-1.17) 0.75	0.17
rs10993994	10q11.23 <i>MSMB</i>	T	1.07 (0.96-1.20) 0.47	1.16 (1.06-1.27) 0.47	0.19
rs12769019	10q26.13 <i>CTBP2</i>	G	1.16 (1.00-1.36) 0.15	1.08 (0.94-1.23) 0.15	0.36
rs7931342	11q13.2	G	1.17 (1.04-1.32) 0.45	1.10 (1.00-1.22) 0.45	0.37
rs11649743	17q12 <i>HNF1B</i>	G	1.14 (0.99-1.32) 0.80	1.10 (0.98-1.25) 0.80	0.69
rs4430796	17q12 <i>HNF1B</i>	A	1.16 (1.03-1.30) 0.53	1.15 (1.05-1.27) 0.53	0.88
rs1859962	17q24.3	G	1.00 (0.89-1.12) 0.42	1.07 (0.97-1.18) 0.42	0.27
rs2735839	19q13 <i>KLK2/3</i>	G	1.03 (0.91-1.17) 0.70	1.09 (0.98-1.21) 0.70	0.33
rs5945572	Xp11.22 <i>NUDT10/11</i>	A	1.27 (1.04-1.55) 0.19	1.31 (1.11-1.54) 0.19	0.84

\*ORs were adjusted for age (quintiles)-ethnicity strata and genome-wide European ancestry (African Americans, Latinos and Native Hawaiians).

$\dagger P_{\text{het}} = P$  value for heterogeneity (advanced versus nonadvanced).

in nephrogenesis, and heterozygous mutations in *HNF1B* are known to cause maturity-onset diabetes of the young (MODY5; ref. 11, 12). *HNF1B* is located on chromosome 17q12 where two independent risk alleles for prostate cancer have been detected in noncoding sequence (2, 5). *KLK3* encodes the prostate-specific antigen protein, which raises the question as to whether the previously reported relationship is causal or an artifact of differential selection of cases and controls based on prostate-specific antigen levels (13, 14). Controls were unselected with regard to prostate-specific antigen level in the present study. A statistically significant positive association was found with the *KLK3* single nucleotide polymorphism for subjects of European and Japanese ancestry, whereas a significant inverse association was found in African Americans. This may suggest that either the variant is not causal and/or that distinct mechanisms are at play in these populations. In addition to the already established 8q24 region, the variants at both 3p12 and 11q13 lie in gene deserts, with the closest annotated genes being ~70 and ~67 kb away, respectively.

In conclusion, we have confirmed that the majority of associations noted with prostate cancer risk variants from genome-wide association studies in European populations can be generalized to other populations. Moreover, they seem to act independently. Deep resequencing and fine-mapping of these regions in samples from multiple populations is now recommended, specifically for loci that display significant ethnic heterogeneity, to both define the full spectrum of risk alleles in the population, as well as further localize the causal alleles.

#### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

#### Acknowledgments

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

From the University of Southern California, we thank Loreall Pooler and David Wong for their laboratory assistance and Hank Huang and Chris Hsu for their technical support.

#### References

1. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. *Nat Genet* 2007;40:316–21.
2. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. *Nat Genet* 2007;39:977–83.
3. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. *Nat Genet* 2008;40:281–3.
4. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. *Nat Genet* 2008;40:310–5.
5. Sun J, Zheng SL, Wiklund F, et al. Evidence for two independent prostate cancer risk-associated loci in the *HNF1B* gene at 17q12. *Nat Genet* 2008;40:1153–5.
6. Haiman CA, Patterson N, Freedman ML, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. *Nat Genet* 2007;39:638–44.
7. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. *Am J Epidemiol* 2000;151:346–57.
8. Lee LG, Connell CR, Bloch W. Allelic discrimination by nick-translation PCR with fluorogenic probes. *Nucleic Acids Res* 1993;21:3761–6.
9. Kote-Jarai Z, Easton DF, Stanford JL, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. *Cancer Epidemiol Biomarkers Prev* 2008;17:2052–61.
10. Nam RK, Reeves JR, Toi A, et al. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis. *J Urol* 2006;175:1291–7.
11. Dudziak K, Mottalebi N, Senkel N, et al. Transcription factor *HNF1B* and novel partners affect nephrogenesis. *Kidney Int* 2008;74:210–7.
12. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. *N Engl J Med* 2001;345:971–80.
13. Ahn J, Berndt SI, Wacholder S, et al. Variation in *KLK* genes, prostate-specific antigen and risk of prostate cancer. *Nat Genet* 2008;40:1032–4.
14. Eeles R, Giles G, Neal D, Muir K, Easton DF, for the PRACTICAL Consortium. Reply to “Variation in *KLK* genes, prostate-specific antigen and risk of prostate cancer.” *Nat Genet* 2008;40:1035–6.

## Generalizability of Associations from Prostate Cancer Genome-Wide Association Studies in Multiple Populations

Kevin M. Waters, Loic Le Marchand, Laurence N. Kolonel, et al.

*Cancer Epidemiol Biomarkers Prev* 2009;18:1285-1289.

<b>Updated version</b>	Access the most recent version of this article at: <a href="http://cebp.aacrjournals.org/content/18/4/1285">http://cebp.aacrjournals.org/content/18/4/1285</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://cebp.aacrjournals.org/content/suppl/2021/03/10/1055-9965.EPI-08-1142.DC1">http://cebp.aacrjournals.org/content/suppl/2021/03/10/1055-9965.EPI-08-1142.DC1</a>

<b>Cited articles</b>	This article cites 13 articles, 1 of which you can access for free at: <a href="http://cebp.aacrjournals.org/content/18/4/1285.full#ref-list-1">http://cebp.aacrjournals.org/content/18/4/1285.full#ref-list-1</a>
<b>Citing articles</b>	This article has been cited by 17 HighWire-hosted articles. Access the articles at: <a href="http://cebp.aacrjournals.org/content/18/4/1285.full#related-urls">http://cebp.aacrjournals.org/content/18/4/1285.full#related-urls</a>

<b>E-mail alerts</b>	<a href="#">Sign up to receive free email-alerts</a> related to this article or journal.
<b>Reprints and Subscriptions</b>	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a> .
<b>Permissions</b>	To request permission to re-use all or part of this article, use this link <a href="http://cebp.aacrjournals.org/content/18/4/1285">http://cebp.aacrjournals.org/content/18/4/1285</a> . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.